Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Performance of CRP as a biomarker for endometriosis

From: A high sensitivity assay is more accurate than a classical assay for the measurement of plasma CRP levels in endometriosis

Authors Type of study Controls Endometriosis Methodology Results
Abrao
et al., 1997
Case-control study N = 15
Time 1
Menstrual phase μg/ml:
1.58 ± 0.31
Time 2:
Proliferative phase μg/ml:
1.53 ± 0.33
N = 35
Stage I-II = 20
Stage III-IV = 15
Menstrual phase μg/ml:
Stage I-II: 5.06 ± 1.32
Stage III-IV: 13.15 ± 2.55
Proliferative phase μg/ml:
Stage I-II: 2.89 ± 0.59
Stage III-IV: 3.52 ± 0.41
Serum
Laparoscopically confirmed or excluded endometriosis
Menstrual and Proliferative phases of cycle
Home-made ELISA
Difference: Time1-Time 2
Controls: 0.05 ± 0.38
Stage I-II: 2.17 ± 1.16
Stage III-IV: 9.63 ± 2.34
Increased levels of CRP in endometriosis (especially for stages III-IV)
Lermann
et al., 2010
Prospective nonrandomized controlled trial N = 34
CRP: 2.88 ± 2.79 ng/ml
hsCRP: 2.48 ± 3.77 ng/ml
N = 48
Stage I: 7
Stage II: 5
Stage III: 18
Stage IV: 18
CRP: 3.54 ± 3.24
hsCRP: 3.61 ± 4.82
Serum
Laparoscopically confirmed or excluded endometriosis
Early Proliferative cycle phase
CRP and hsCRP methods (details Not Available)
NS differences
Matarese
et al., 2000
Case-control study N = 15 N = 13
Stage I-II: 7
Stage III-IV: 6
Serum
Laparoscopically confirmed or excluded endometriosis
Proliferative and secretive cycle phase
N Latex CRP monokit (Bering Nephelometer Systems)
CRP serum concentrations were less than 3.5 mg/L in all subjects
Mihalyi
et al., 2010
Case-control study N = 93
All phases:
0.64 (0.11-15.03) mg/L
Secretory phase
0.56 (0.11-14.14) mg/L
N = 201
All phases
Stage III-IV:
1.35 (0.23-34.78) mg/L
Secretory phase
Stage I-IV:
0.88 (0.12-27.23) mg/L
EDTA Plasma
Laparoscopically confirmed or excluded endometriosis
Menstrual, Proliferative and Secretory phases
hsCRP method: HS Tina-quant CRP (latex) hs assay (Roche, Vilvoorde, Belgium)
Significant increase in Stage III-IV (independent of cycle phase and in the luteal phase (p < 0.0001; p = 0.001respectively)
Significant increase in Stage I-IV of endometriosis in the luteal phase (p = 0.03)
Xavier
et al., 2005
Case-control study N = 13
Early proliferative:
0.68 (0.19-2.22) mg/L
Late proliferative:
0.59 (0.21-1.28) mg/L
Early secretory:
0.90 (0.42-2.31) mg/L
Late secretory:
0.87 (0.22-1.52) mg/L
N = 25
Stage III-IV
Early proliferative:
2.29 (0.70-3.54) mg/L
Late proliferative:
1.10 (0.30-2.06) mg/L
Early secretory:
1.09 (0.39-2.62) mg/L
Late secretory:
0.60 (0.28-3.19) mg/L
Serum
Early and late Proliferative phase
Early and late Secretory phase
hsCRP two-site homemade ELISA
NS differences